
Becton, Dickinson and Company Investor Relations Material
Latest events

Q3 2025
Becton, Dickinson and Company
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Becton, Dickinson and Company
Access all reports
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's principal businesses are based upon its expertise in the areas of vascular access devices (VADs), hemostasis systems and technologies, bioscience research tools for cell culture reagents and assays, transfusion technologies through a majority ownership interest in C.R. Bard Incorporated; Point-of-care testing instruments covering blood collection with red cell alloimmunization detection capability; transcutaneous immunoglobulin (Ig) replacement therapy; nutritionals.
Key slides for Becton, Dickinson and Company


Q3 2025
Becton, Dickinson and Company


Q1 2025
Becton, Dickinson and Company
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
BDX
Country
🇺🇸 United States